Efficacy and Drug Competitiveness of New Mechanism 'CXCR7 Agonist'
Demonstrated in Research
IRID BMS, a new drug research and development company of Ildong Pharmaceutical Group, announced on the 1st that it unveiled its new drug candidate in the field of cardiovascular diseases at the American College of Cardiology (ACC).
'ACC' is the world's most prestigious cardiology society leading research, treatment development, and guideline provision in the cardiovascular field. This year's event was held in Chicago, USA, from the 29th to the 31st of last month.
IRID BMS presented the non-clinical research results related to its innovatively developed new drug candidate for cardiovascular diseases, 'IL21120033,' in poster format.
According to IRID BMS, 'IL21120033' is a small molecule compound with a CXCR7 agonist mechanism. In heart failure animal models, it demonstrated superior improvement in cardiac output and inhibition of cardiac fibrosis compared to existing treatments (sacubitril/valsartan formulations), confirming its competitiveness and differentiation.
Non-clinical research results showed that 'IL21120033' significantly reduced the infarcted area of the left ventricle and greatly lowered the levels of CK-MB3 and cTnI, markers of cardiac injury. Additionally, along with increased cardiac output, anti-inflammatory and anti-fibrotic effects were also observed.
An IRID BMS official explained, "CXCR7 is known to play an important role in suppressing cardiac cell death when ischemia or damage occurs in the heart," adding, "Through a new approach using a small molecule compound with a CXCR7 agonist mechanism, we expect to develop a drug that can be applied to various cardiovascular diseases."
Meanwhile, as IRID BMS has confirmed the potential of this innovative new drug to treat fibrosis-related cardiovascular diseases such as ischemic heart disease, arrhythmia, and heart attack through prior studies, it plans to accelerate preparations for clinical development, including GLP (safety evaluation) testing and IND (clinical trial application) approval.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
